cyrilzakka/clinical-trials huggingface dataset:
Exercise Intensity, Metabolic Rate and Insulin Sensitivity

The primary goal is to test the hypothesis high interval exercise increases energy expenditure and Insulin sensitivity more than 2 days of rest or moderate intensity exercise cumulatively over 23 hours during and following the exercise. Secondary goals are to evaluate exercise difficulty during moderate intensity exercise and high interval exercise as well as difficulty of activities of daily living and free living physical activity following rest, moderate intensity exercise and high interval exercise.

A secondary study is designed to evaluate potential mechanism. Hypotheses are that changes in muscle lipid metabolism, mitochondrial function, fat and cellular insulin signals will be increased following the high intensity interval exercise. In addition, these changes will be related to changes in insulin sensitivity and increases in protein metabolism and muscle damage.


Eligibility Criteria:
Inclusion Criteria:

* healthy premenopausal African-American or Caucasian women ages 19 - 42

Exclusion Criteria:

* subjects cannot be smoking,
* taking medications which alter energy expenditure or fuel utilization,
* be diabetic or have a body mass index (BMI) less than 18 or more than 35.
* Also subjects cannot be pregnant or have cardiopulmonary disease.
Validation of the Chinese Version of the SECONDs

The aim of this study was to translate the SECONDs from English into Chinese and determine the validity of this Chinese version

The assessment is of great importance for the management and treatment in patients with disorders of consciousness. The Simplified Evaluation of CONsciousness Disorders is a useful tool to assess consciousness of DOC patients in bedside. The aim of this study was to translate the SECONDs from English into Chinese and determine the validity of this Chinese version. To test internal reliability and inter-rater reliability, both rater A and rater B assess the perception of pain on day 1; and to obtain test-retest reliability, rater A assessed all patients repeatedly on day 2.

Eligibility Criteria:
Inclusion Criteria:

* age ≥ 16 years old;
* no administration of neuromuscular blockers or sedation within the 24 hours of enrolment;
* the presence of periods of eye opening (indicating wakefulness and rest cycles);
* a diagnosis of VS or MCS, based on more than 4 times behavioral assessment performed using the Coma Recovery Scale-Revised within 2 weeks.

Exclusion Criteria:

* Coma;
* documented history of prior brain injury;
* psychiatric or neurologic illness;
* neuromuscular blocking agents or sedative drugs administered within the prior 24 hours;
* no documented history of a prior coma, critical illness or unstable medical condition;
* upper limb contusions, fractures (based on the imaging examination) or flaccid paralysis (by using noxious stimuli to upper limbs, motor sub-scale scores \<1).
Use of a Smart-phone Based Medication Adherence Platform to Improve Outcomes in Uncontrolled Non-insulin Dependent Diabetes Among Veterans

The purpose of this study is to determine if a novel smartphone-based medication adherence platform accompanied by directed pharmacist intervention can improve A1c control and medication compliance in non-insulin dependent diabetics.

This study will employ a case-crossover design where patients will undergo both a standard of care arm as well as an intervention arm (See Figure 1). Half of the study participants will be randomized and enrolled in the standard of care arm for the initial 3 months and then transition to the intervention arm for 3 months. The remaining patients will be enrolled in the intervention arm for the initial 3 months and then transitioned to the standard of care arm.

Primary outcomes will be the change from pre-intervention baseline in hemoblobin A1c (HgA1c) between the Dayamed Arthur platform and standard of care.

Secondary outcomes will include change in MAS, the change in RMA from week 1 of intervention arm to week 12, comparison of historical MPR and PDC with patient's RMA at week 1 of intervention arm, and correlation of change in RMA and MAS score during intervention arm. Furthermore, we will measure sustained change in MAS in the patient population who begin study in the intervention arm and are subsequently transitioned to standard of care. We will also collect information patient usability/acceptability and provider satisfaction with the Dayamed Arthur platform.

Exploratory outcomes will include potential reduction in healthcare resource utilization based on avoidance of therapy escalation in patients with improved compliance, as well as psychosocial factors associated with improved adherence

Reduction of HgbA1c by 0.5% from pre-intervention baseline for individuals on the DayaMed intervention compared to standard of care

Eligibility Criteria:
Inclusion Criteria:

* Assigned primary care provider at VA Sierra Nevada Healthcare System (VASNHCS)
* Diagnosis of type 2 diabetes
* Own a smart phone/tablet
* HgbA1c drawn at or within 30 days of study enrollment.
* Uncontrolled A1c defined as an A1c \>9 in the following order of preference

  * Last 3 A1cs \>9% in the last 2 year
  * Last 2 A1cs \>9% in the last 2 years
  * Last A1c \>9% in the last 2 years
  * 2-year average A1c \>9%

Exclusion Criteria:

* Actively on insulin therapy
* Unable to install DayaMed application onto their phone/tablet
* Unable to load medications
Urgent Medical and Surgical Conditions During Flights

The aim of this study is to evaluate the incidence and status of urgent medical conditions. After defining the urgent situations, the investigators will evaluate the adequacy of the standard medical kits and trainings.

In this study, the incidence and status of urgent medical conditions, the attitudes of health professionals who encounter such conditions, adequacy of Aerospace Medical Association (ASMA) suggested medical kits and training of cabin crew in data-received-company aircrafts and the demographic data of patients have been evaluated.

Eligibility Criteria:
Inclusion Criteria:

* All passengers (no age limitations) needed urgent medical support during flights

Exclusion Criteria:

* Patients whom medical urgency records are insufficient
Closed-Loop Target Controlled Infusion in Laparoscopic Cholecystectomy

Laparoscopic Cholecystectomy applied to Artificial pneumoperitoneum and the extent of Surgical stimulation cause the wave of hemodynamics increase vigorously, which make it difficult to judge the depth of anesthesia according to traditional hemodynamics index such as heart rate and blood pressure.In case of this, the investigators design this research to study the Closed-Loop Target Controlled Infusion to anaesthesia of individualization guided by a Narcotrend index monitor in Laparoscopic Cholecystectomy.

Anesthetics alter electrocortical activity in a dose-dependent manner,and it is suggested that electroencephalographic(EEG)activity can provide a reliable basis for a surrogate measurement of hypnosis.An EEG monitor,the Narcotrend Index(NI),has proven useful to titrate hypnotic drugs.Because it is a single composite measure monitored continuously,it has been used in controlled studies to automatically guide propofol administration.Conversely,automated delivery systems for opioids have seldom been described using EEG activity There are no specific measures to quantify analgesia directly.Nevertheless,in the interaction between opioid-hypnotic synergy and loss of consciousness,when the dose of analgesic administered is sufficient to inhibit autonomic response to noxious stimuli,then the required hypnotic concentration is only that needed to achieve loss of consciousness.Moreover,a noxious stimulus such as laryngoscopy or periosteal pressure to the tibia may cause electrocortical activation with an increase in Narcotrend index,which indirectly reflects the analgesic state or the level of antinociception.Finally,an excitatory EEG arousal reaction resulting from nociceptive stimulation can provide a rational basis for analgesia administration.It can then be hypothesized that Narcotrend index could also be the controlled variable for opioid administration.

Eligibility Criteria:
Inclusion Criteria:

1. require general anesthesia
2. expected to last\>30 minutes
3. 18\~90 years
4. ASA Ⅰ\~Ⅳ level

Exclusion Criteria:

1. psychiatric illness
2. supraspinal neurological disorders
3. cranial neurosurgical procedures
4. patients equipped with a pacemaker
Impact of Percutaneous Closure of the Left Atrial on the Maximum Proto-diastolic Speed of the Mitral Ring Measured by Tissue Doppler (ACTIFER)

The main objective is to demonstrate the equivalence, before and after the percutaneous closure of the left atrial procedure, of the maximum proto-diastolic velocity of the lateral mitral annulus (e 'lat) measured by tissue Doppler. Patients with AF at high embolic risk and presenting a formal and definitive contraindication to anticoagulants having been operated on for percutaneous closure of the left atrial by St Jude AMULET device, considering an equivalence margin of 1 cm / sec.


Eligibility Criteria:
Inclusion Criteria:

* Man or woman over 18 years-old
* Patient with paroxysmal AF at high embolic risk (CHA2DS2Vasc score ≥ 4) and presenting a formal and definitive contraindication to anticoagulants
* Patient scheduled for percutaneous closure of the left auricle by St Jude AMULET device
* Patient in sinus rhythm
* Subject affiliated or beneficiary of a social security scheme
* Patient having signed the informed consent

Exclusion Criteria:

* Patient participating in another clinical study
* Patient in permanent ACFA
* Patient with a mitral prosthesis (biological or mechanical),
* Patient with a history of mitral annuloplasty
* Protected patient: adult under guardianship, curatorship or other legal protection, deprived of liberty by judicial or administrative decision;
* Pregnant, breastfeeding or parturient woman;
* Patient hospitalized without consent.
The Impact of Rockall Risk Scoring System on Management of Upper Gastrointestinal System Bleeding

The patients who admit to emergency department with upper gastrointestinal system bleeding will undergo a clinical evaluation with Rockall Risk Scoring System. The patients with Rockall score of 1 or less will be discharged with medical treatment, and will have an elective upper gastrointestinal endoscopy in the end of the 30th day. The impact of Rockall Risk Scoring System on assessing the necessity of emergency endoscopy, length of hospital stay, morbidity, and mortality in low-risk patients will be evaluated.

The patients who admit to emergency department with symptoms of upper gastrointestinal system bleeding will undergo a clinical evaluation. First, diagnosis of upper gastrointestinal system bleeding will be established by combined physical examination and nasogastric tube application. After a certain diagnosis, all of the patients will be scored according to Rockall Risk Scoring System. The patients with a 1 or less Rockall score will have conservative treatment including mucosal protective agent (sucralfat), proton pump inhibitors (omeprazole, lansoprazole, pantoprazole), and hemodynamic monitorization. Should Rockall score and hemodynamic parameters remain unchanged or get improved in the end of 6 hours after admission, oral feeding will be started and the patient will be discharged with anti-ulcer medication (mucosal protective agent and proton pump inhibitor, PO). These patients will be scheduled for upper gastrointestinal endoscopy at 30th day. The patients who have: an initial Rockall score of 2 or greater, an increase in Rockall score or deterioration in hemodynamic parameters during observation, will have emergency endoscopy and will be excluded from the study.

Eligibility Criteria:
Inclusion Criteria:

* Clinical diagnosis of upper gastrointestinal system bleeding
* Rockall score of 1 or less
* Volunteers
* Agreement with the terms of informed consent

Exclusion Criteria:

* Uncertain clinical diagnosis of upper gastrointestinal system bleeding
* Rockall score of 2 or greater
* Deterioration in hemodynamic parameters during follow-up
* Unwilling patients to join the study
* Disagreement with the terms of informed consent
Electroacupuncture for Sciatica Due to Intervertebral Disc Displacement

This multicenter randomized controlled trial (RCT) will evaluate the therapeutic effectiveness and health-economics of electroacupuncture for sciatica due to intervertebral disc displacement in 3 compared groups: electroacupuncture, electroacupuncture plus traction, electroacupuncture plus traction and medication.

This is a multicenter RCT with 3 groups to determine the effectiveness and health economic evaluation of the electroacupuncture for sciatica due to intervertebral disc displacement in a population of adults aged 18-65. 324 participants who meet the inclusion criteria will be randomly allocated into 3 different groups, namely electroacupuncture group, electroacupuncture \& traction group, electroacupuncture \& traction \& oral medication group.

All participants will receive six-week treatment, the participants in electroacupuncture group will receive electroacupuncture only, electroacupuncture \& traction group will receive both electroacupuncture and traction, and in electroacupuncture \& traction \& oral medication group all of the three therapies are adopted.

The statistical analysis will be conducted by a third party who is masked to the allocation of participants.

Eligibility Criteria:
Inclusion Criteria:

* Patients who meet the clinical diagnosis of sciatica caused by intervertebral disc displacement;
* Male or female, aged 18-65;
* Have completed informed consent form.

Exclusion Criteria:

* Patients with sciatica caused by diseases such as piriformis syndrome, thickening of ligamentum flavus, acute lumbar strain, contusion, congenital spina bifid, lumbar and sacrum deformity, lumbar sacral vertebra joint disorder or proliferative osteoarthrosis;
* Patients with urinary and fecal incontinence caused by acute lumbar disc herniation, huge or central type lumbar disc herniation sufferer in need of surgery;
* Patients who fail to finish the basic treatment course, or have poor adherence;
* Patients having a poor state, particularly unconsciousness, psychopath, severe osteoporosis, concurrent infection or bleeding susceptibly, or accompany with primary diseases in cardiovascular, digestion or hemopoietic systems and viscera as kidney, liver;
* Pregnant or lactating women;
* Patients in other clinical research.
Associations of Plasma Vanadium Concentrations With Gestational Diabetes Mellitus

Background: Vanadium compounds have been shown to exert insulin-mimetic effects and thereby control glucose homeostasis. However, studies regarding the levels of vanadium and gestational diabetes mellitus (GDM) are limited and have inconsistent outcomes.

Objective: The aim of this study was to investigate the association of plasma vanadium concentrations with gestational diabetes mellitus (GDM).

Design: A hospital-based case-control study was carried out in urban Wuhan, China from August 2012 to April 2015. Pregnant women who screened for GDM at the outpatient clinics of the Department of Endocrinology, Tongji Hospital were invited to participant in the study. The inclusion criteria were as follows: 1) age ≥ 20 and ≤ 43 years; 2) gestational age at GDM screening ≥ 24 weeks; 3) singleton pregnancy. The investigators excluded women who met any of the following items: history of diabetes (including but not limited to GDM), cardiovascular disease, cancer or other systemic diseases; pharmacologic treatment or dietary supplement use that might influence glucose or lipids metabolism; accompanied by other pregnancy complications; incomplete basic information. The diagnosis of GDM can be made if one or more glucose values are above the cut points of 5.1, 10.0 and 8.5 mmol/L at fasting, 1 and 2 h during a 75-gram oral glucose tolerance test (OGTT). Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity. Finally, 252 GDM cases and 252 matched controls were selected in this study. All participants gave written informed consent before enrolling in the study. Fasting blood samples (≥ 8 h overnight fasting) were collected using anticoagulant tubes and centrifuged at 3000 rpm for 5 min. Plasma were separated from blood cells and stored at -80 ℃ for further assay. Plasma vanadium concentrations were measured using inductively coupled plasma mass spectrometry. Conditional logistic regression and restricted cubic spline model were used to evaluate the associations between plasma vanadium and odds of GDM.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 20 and ≤ 43 years;
* Gestational age at GDM screening ≥ 24 weeks;
* Singleton pregnancy;

Exclusion Criteria:

* History of diabetes (including but not limited to GDM), cardiovascular disease, cancer or other systemic diseases;
* History of receiving pharmacological treatment known to affect glucose metabolism;
* Incomplete basic information.
A Comprehensive Assessment of Trunk, Scapula and Upper Limb in Neurological Patients. Reliability, Validity and Interrelatedness

The study aimed to provide insights in the coordination between trunk, shoulder and upper limb while reaching. Two main phases are present in this study:

In phase A: the psychometric properties of two tests: Clinical Scapular protocol (ClinScaP) in PwMS (Persons with Multiple Sclerosis) and healthy controls.

1. To investigate the test-retest reliability of the Clinical Scapular Protocol (ClinScaP) and the Reaching Performance Scale (RPS) in PwMS
2. To investigate the discriminative of the ClinScaP between PwMS and healthy controls
3. To investigate the discriminative of the RPS between PwMS and healthy controls
4. To investigate the concurrent validity of ClinScaP and RPS in PwMS, compared with upper limb dysfunction measurements.

   In phase B:
5. To investigate the prevalence of trunk, scapula and upper limb impairments in PwMS and stroke patients.
6. To investigate the interaction between trunk, scapula and upper limb impairments in PwMS and stroke patients.


Eligibility Criteria:
Inclusion criteria for all participants: Healthy controls, PwMS (Persons with Multiple Sclerosis) and stroke patients

* Age \> 18 years
* Able to understand and execute the test instructions
* Able to sit on a chair with low back support for 10 minutes

Inclusion criteria specific for PwMS:

* Diagnosed with MS (Multiple Sclerosis) using McDonald criteria
* Able to move at least 1 out of 3 joints (wrist, elbow or shoulder): Medical Research Council score 3.

Inclusion criteria for stroke patients:

* First- ever single, unilateral (ischemic or hemorrhagic) stroke
* No apraxia or hemi spatial neglect
* Able to move at least 1 out of 3 joints of the affected upper limb (wrist, elbow or shoulder): Medical Research Council score 3.

Exclusion Criteria:

* Other medical conditions interfering with the upper limb function or trunk (orthopedic or rheumatoid impairment)
* Perceived pain in one of the upper limbs of more than 4/10 (Visual Analog Scale)
* Severe cognitive or visual deficits interfering with testing
* For the PwMS: a relapse or relapse-related treatment in the last month prior to the study
Early Diagnosis of Clinical Evolution From SARS-CoV-2

The aim of the CORONA.BOT project is to exploit the Artificial Intelligence methods of Generator Real World Data Facility to automatically extract structured and unstructured data from hospital databases and to implement an early risk assessment (warning system) regarding the negative outcome for patients infected with SARS-CoV-2.

The objective of CORONABED.BOT is to analyze the care pathways of patients from the same cohort as CORONA.BOT, in order to identify the total length of stay, intensive care occupations and flows between departments, based on variables demographics and first entry clinics Early identification of patients with symptoms compatible with SARS-CoV-2 infection will enable more rapid activation of isolation procedures, contact monitoring/contact history and decisions on the most appropriate clinical pathway in terms of type of treatment and unit. Similarly, the identification of factors correlated with worse outcomes will allow more effective planning for the use of critical resources (such as intensive care and others).


Eligibility Criteria:
Inclusion Criteria:

* adult patients (18 years of age or older)
* admitted to the Gemelli and Columbus Polyclinic
* diagnosis of SARS-CoV-2 infection (suspected cases will also be included).

Exclusion Criteria:

* aaaa
Sorafenib in BAC or Never-Smokers With Lung Adenocarcinoma

Open label study of sorafenib

Open label study using oral sorafenib 800 mg daily in any stage III-IV BAC lung cancer and Stage III-IV adenocarcinoma of the lung in nonsmokers (less than \< 100 cigarettes lifetime).

Eligibility Criteria:
Inclusion Criteria:

* Age \> 18
* Life expectancy \> 12 weeks
* Biopsy-proven BAC or adenocarcinoma
* Willing to provide smoking status
* Selected IIIB or stage IV cancer that is incompletely resected or unresectable

Exclusion Criteria:

* O2 saturation \< 88% on room air
* Pregnant or nursing women
* Surgery or radiation therapy within 4 weeks of starting study
* Major heart condition within 6 months of starting therapy
* Certain concomitant medications prohibited